These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19717481)

  • 1. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial.
    Tashkin DP; Celli B; Kesten S; Lystig T; Mehra S; Decramer M
    Eur Respir J; 2010 Feb; 35(2):287-94. PubMed ID: 19717481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial.
    Troosters T; Celli B; Lystig T; Kesten S; Mehra S; Tashkin DP; Decramer M;
    Eur Respir J; 2010 Jul; 36(1):65-73. PubMed ID: 20185426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT).
    Morice AH; Celli B; Kesten S; Lystig T; Tashkin D; Decramer M
    Respir Med; 2010 Nov; 104(11):1659-67. PubMed ID: 20724131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of tiotropium in COPD patients from Asia: a subgroup analysis from the UPLIFT trial.
    Fukuchi Y; Fernandez L; Kuo HP; Mahayiddin A; Celli B; Decramer M; Kesten S; Liu D; Tashkin D
    Respirology; 2011 Jul; 16(5):825-35. PubMed ID: 21539680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 4-year trial of tiotropium in chronic obstructive pulmonary disease.
    Tashkin DP; Celli B; Senn S; Burkhart D; Kesten S; Menjoge S; Decramer M;
    N Engl J Med; 2008 Oct; 359(15):1543-54. PubMed ID: 18836213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of tiotropium on the course of moderate-to-very severe chronic obstructive pulmonary disease: the UPLIFT trial.
    Tashkin DP
    Expert Rev Respir Med; 2010 Jun; 4(3):279-89. PubMed ID: 20524910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.
    Decramer M; Celli B; Kesten S; Lystig T; Mehra S; Tashkin DP;
    Lancet; 2009 Oct; 374(9696):1171-8. PubMed ID: 19716598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tiotropium in COPD patients with FEV1 ≥ 60% participating in the UPLIFT® trial.
    Tashkin DP; Celli BR; Decramer M; Lystig T; Liu D; Kesten S
    COPD; 2012 Jun; 9(3):289-96. PubMed ID: 22432932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial.
    Tashkin D; Celli B; Kesten S; Lystig T; Decramer M
    Respir Med; 2010 Oct; 104(10):1495-504. PubMed ID: 20418083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bronchodilator responsiveness in patients with COPD.
    Tashkin DP; Celli B; Decramer M; Liu D; Burkhart D; Cassino C; Kesten S
    Eur Respir J; 2008 Apr; 31(4):742-50. PubMed ID: 18256071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
    Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease.
    Celli B; Decramer M; Kesten S; Liu D; Mehra S; Tashkin DP;
    Am J Respir Crit Care Med; 2009 Nov; 180(10):948-55. PubMed ID: 19729663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone.
    Kurashima K; Hara K; Yoneda K; Kanauchi T; Kagiyama N; Tokunaga D; Takayanagi N; Ubukata M; Sugita Y
    Respirology; 2009 Mar; 14(2):239-44. PubMed ID: 19210650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium in COPD patients not previously receiving maintenance respiratory medications.
    Adams SG; Anzueto A; Briggs DD; Menjoge SS; Kesten S
    Respir Med; 2006 Sep; 100(9):1495-503. PubMed ID: 16698259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study.
    Jung KS; Park HY; Park SY; Kim SK; Kim YK; Shim JJ; Moon HS; Lee KH; Yoo JH; Lee SD; ;
    Respir Med; 2012 Mar; 106(3):382-9. PubMed ID: 21975275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The UPLIFT study (Understanding Potential Long-term Impacts on Function with Tiotropium)].
    Corhay JL; Louis R
    Rev Med Liege; 2009 Jan; 64(1):52-7. PubMed ID: 19317104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additive benefits of tiotropium in COPD patients treated with long-acting beta agonists and corticosteroids.
    Perng DW; Wu CC; Su KC; Lee YC; Perng RP; Tao CW
    Respirology; 2006 Sep; 11(5):598-602. PubMed ID: 16916333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease.
    Verkindre C; Bart F; Aguilaniu B; Fortin F; Guérin JC; Le Merre C; Iacono P; Huchon G
    Respiration; 2006; 73(4):420-7. PubMed ID: 16484769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
    Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
    Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium improves FEV1 in patients with COPD irrespective of smoking status.
    Moita J; Bárbara C; Cardoso J; Costa R; Sousa M; Ruiz J; Santos ML
    Pulm Pharmacol Ther; 2008; 21(1):146-51. PubMed ID: 17693107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.